Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
This piece explains withdrawal rate concepts for index fund retirement planning, outlining how to set sustainable rates and monitor portfolio health.
22,391 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
XDTE uses daily 0DTE call selling to generate income from the S&P 500. This piece explains how the fund works, what i...
Chevron stock has cooled from a $209 peak, leaving investors weighing dividend coverage, cash flow, and growth amid v...
Fundstrat’s Granny Shots ETF outperforms the S&P 500 through mid-2026, fueling debate as Tom Lee raises the odds of a...
The SPDR S&P Metals & Mining ETF (XME) has surged toward a near-double over the past year, buoyed by gold and copper ...
A private equity firm just disclosed a sizable stake in Disc Medicine, signaling growing confidence in its red blood ...
A high-profile hedge fund reveals a fresh stake in Clearwater Analytics, the investment accounting platform. We break...
Mega-cap leadership keeps steering the bull market. AIC rally and AI-driven spend lift MGK, SCHG, and IWF as investor...
YieldMax’s ULTY ETF has paid out consistently high weekly distributions, yet two-year data show a stark mismatch betw...
SEA’s December 2025 payout fell 60% from 2024, exposing how its dividend is tied to cyclical freight profits rather t...
A notable fund just built a fresh position in a cloud security leader. Discover the numbers behind winmill loads qual...
NATO defense budgets surged to fresh records as members commit to larger, longer-term modernization. Three ETFs offer...